Free Trial
NASDAQ:HYPD

Hyperion DeFi Q1 2025 Earnings Report

Hyperion DeFi logo
$3.64 -1.03 (-22.06%)
Closing price 05/6/2026 04:00 PM Eastern
Extended Trading
$3.66 +0.02 (+0.69%)
As of 04:07 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Hyperion DeFi EPS Results

Actual EPS
-$1.59
Consensus EPS
-$7.20
Beat/Miss
Beat by +$5.61
One Year Ago EPS
N/A

Hyperion DeFi Revenue Results

Actual Revenue
$1.60 million
Expected Revenue
$1.60 million
Beat/Miss
Met Expectations
YoY Revenue Growth
N/A

Hyperion DeFi Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Sunday, May 18, 2025
Conference Call Time
6:00PM ET

Hyperion DeFi Earnings Headlines

Ticker Revealed: Pre-IPO Access to "Next Elon Musk" Company
We’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.tc pixel
Analyzing PharmaTher (OTCMKTS:PHRRF) & Hyperion DeFi (NASDAQ:HYPD)
See More Hyperion DeFi Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Hyperion DeFi? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Hyperion DeFi and other key companies, straight to your email.

About Hyperion DeFi

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

View Hyperion DeFi Profile